Houlihan Financial Resource Group Ltd. Cuts Stock Position in Amgen Inc. (NASDAQ:AMGN)

Houlihan Financial Resource Group Ltd. decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,416 shares of the medical research company’s stock after selling 90 shares during the quarter. Houlihan Financial Resource Group Ltd.’s holdings in Amgen were worth $890,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Icon Wealth Advisors LLC increased its position in shares of Amgen by 3,955.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 169,748 shares during the last quarter. Larson Financial Group LLC increased its holdings in Amgen by 29.2% in the third quarter. Larson Financial Group LLC now owns 1,021 shares of the medical research company’s stock valued at $329,000 after buying an additional 231 shares during the last quarter. Summit Trail Advisors LLC raised its stake in Amgen by 40.1% in the third quarter. Summit Trail Advisors LLC now owns 7,552 shares of the medical research company’s stock valued at $2,433,000 after buying an additional 2,163 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in Amgen by 21.3% during the 3rd quarter. Fisher Asset Management LLC now owns 102,352 shares of the medical research company’s stock worth $32,979,000 after buying an additional 17,974 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd boosted its position in shares of Amgen by 44.9% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 27,496 shares of the medical research company’s stock worth $8,856,000 after acquiring an additional 8,524 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on AMGN shares. Citigroup restated a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Johnson Rice set a $294.00 target price on shares of Amgen in a research report on Wednesday, March 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Finally, Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $314.04.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by company insiders.

Amgen Stock Down 0.5 %

Shares of NASDAQ:AMGN opened at $314.38 on Tuesday. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm’s 50-day simple moving average is $298.13 and its 200-day simple moving average is $298.50. The company has a market cap of $168.89 billion, a price-to-earnings ratio of 41.64, a PEG ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.03%. The ex-dividend date is Friday, May 16th. Amgen’s payout ratio is 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.